Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

This study investigated the activity of lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Lenalidomide was given at 10 mg daily with dose escalation up to 25 mg daily. Three patients (7%) achieved a complete response (CR), one a nodular partial remission, and 10 patients a partial remission (PR), for an overall response (OR) rate of 32%. Treatment with lenalidomide was associated with an OR rate of 31% in patients with 11q or 17p deletion, of 24% in patients with unmutated V(H), and of 25% in patients with fludarabine-refractory disease. The most common toxicity was myelosuppression, and the median daily dose of lenalidomide tolerated was 10 mg. Plasma levels of angiogenic factors, inflammatory cytokines, and cytokine receptors were measured at baseline, day 7, and day 28. There was a dramatic increase in median interleukin (IL)-6, IL-10, IL-2, and tumor necrosis factor receptor-1 levels on day 7, whereas no changes were observed in median vascular endothelial growth factor levels (20 patients studied). According to our experience, lenalidomide given as a continuous treatment has antitumor activity in heavily pretreated patients with CLL.

[1]  M. Rozman,et al.  Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents. , 2008, Cytokine.

[2]  B. Sander,et al.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q− syndrome patients , 2007, Proceedings of the National Academy of Sciences.

[3]  N. Munshi,et al.  Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment , 2007, Journal of cellular biochemistry.

[4]  H. Kantarjian,et al.  The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy , 2007, Leukemia & lymphoma.

[5]  M. Czuczman,et al.  Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Diane Warren,et al.  A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. , 2006, Blood.

[7]  J. Reuben,et al.  Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma , 2006, Cancer.

[8]  M. Gordon.  Efficacy of Lenalidomide in Myelodysplastic Syndromes , 2006 .

[9]  G. Tricot,et al.  Immunomodulatory drugs in multiple myeloma , 2005, Expert opinion on investigational drugs.

[10]  M. Grever,et al.  Changing the way we think about chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Andreeff,et al.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Rassidakis,et al.  Expression of bcl-3 in chronic lymphocytic leukemia correlates with trisomy 12 and abnormalities of chromosome 19. , 2005, American journal of clinical pathology.

[13]  H. Pandha,et al.  Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers , 2004, British Journal of Cancer.

[14]  A. Dalgleish,et al.  Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects , 2002, British Journal of Cancer.

[15]  Z. Estrov,et al.  The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia , 2002 .

[16]  J. Byrd,et al.  Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.

[17]  B. Villoutreix,et al.  3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. , 2002, Blood.

[18]  H. Kantarjian,et al.  Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia , 2002, Leukemia & lymphoma.

[19]  H. Goldschmidt,et al.  Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion , 2001, British journal of haematology.

[20]  A. Dalgleish,et al.  Immunotherapeutic and antitumour potential of thalidomide analogues , 2001, Expert opinion on biological therapy.

[21]  N. Kay,et al.  Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia , 2000, Leukemia.

[22]  P. Haslett,et al.  Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.

[23]  M. Grever,et al.  National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. , 1996, Blood.

[24]  P. Thall,et al.  Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.

[25]  Richard Simon,et al.  A Bayesian approach to establishang sample size and monitoring criteria for phase II clinical trials , 1994 .

[26]  R. D'Amato,et al.  Thalidomide is an inhibitor of angiogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P F Thall,et al.  A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials. , 1994, Controlled clinical trials.

[28]  H. Tilg,et al.  Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. , 1994, Blood.

[29]  C. Dinarello,et al.  Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. , 1990, Blood.